Restoring the Balance in the Brain
Gabather is a pharmaceutical company developing the next generation of therapeutics for neuropsychiatric disorders, based on the ability of our proprietary drug candidates to restore the balance in the brain and enhance cognitive function.
Our most advanced drug candidate, GT-002, has completed phase I clinical trials. GT-002 has been shown to have excellent pharmacokinetics, as well as being safe and well-tolerated.
Our vision is to bring novel transformative medicine to the patient to treat psychiatric disorders in a fast and effective way.
Gabather has four focus areas with huge unmet medical needs: anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease.
We believe our innovative drug development approach offers unique opportunities to develop potentially transformative medicines that will achieve our main goal, providing improved treatments of mental diseases in an effective way.
We have more than 10 years of research at both Lund University and the Research Institute of Biological Psychiatry in Roskilde as the basis for our development projects.
Here you will find the latest press releases from Gabather. You can find more in our Investors section. Certain news are only published in Swedish.